Peapack Gladstone Financial Corp increases its stake in
Regeneron Pharmaceuticals, and analysts list it among the most profitable stocks to buy because of its extreme profits. However, a lawsuit notice has been issued for those who hold
Regeneron shares. Many other financial institutions such as the
Massachusetts Financial Services,
FIL Ltd,
Treasurer of the State of North Carolina, and
APG Asset Management N.V. have tweaked their holdings in the company recently. Despite Dupixent approval in Japan,
Regeneron shares fell 10% over the last week. An interesting development is that Jim Cramer wants you to ‘own’ Regeneron shares.
May 23rd options for
Regeneron are now available. Meanwhile,
Regeneron is facing mounting pressure on sales and legal fronts. Some analysts consider
Regeneron among the best biotech stocks to buy even though it is performing poorly on the large cap front. As some doubts arise about
Regeneron’s transparency, investors are suing over Eylea pricing practices.
Regeneron is called out for resilient franchise and robust free cash flow, it now also has a lawsuit alert.
Regeneron reported large earnings growth but lags behind 11% CAGR delivered to shareholders. The market shifts caused
Regeneron to touch a 52-week low recently.
Regeneron Pharmaceuticals REGN News Analytics from Tue, 14 Jan 2025 08:00:00 GMT to Sun, 13 Apr 2025 00:06:53 GMT -
Rating 0
- Innovation -3
- Information 7
- Rumor -2
